A novel algorithm to improve specificity in ovarian cancer detection.

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Autoantibodies (AAbs) to tumor-associated antigens are explored for early ovarian cancer detection.
• A multiplex immunoassay approach was developed to evaluate p53 protein and its peptide epitopes for AAb detection.

Purpose of the Study:

• To assess the utility of p53 autoantibodies in detecting ovarian cancer.
• To enhance specificity and sensitivity in differentiating between healthy women and those with ovarian cancer.

Main Methods:

• A multiplex immunoassay using Luminex technology detected AAbs to p53 full-length protein and 20-mer overlapping peptide epitopes.
• The assay was performed on 359 sera from healthy women and 285 from ovarian cancer patients.
• CA-125 levels were measured in p53 AAb-positive sera.

Main Results:

• A combined approach using full-length p53 protein and peptide epitopes, with optimized cutoffs, reduced false positives to 1/359.
• Seven ovarian cancer patients negative for CA-125 were identified (26% of p53 AAb-positive patients).

Conclusions:

• Combining p53 autoantibody measurements to full-length protein and selected epitopes can improve ovarian cancer detection specificity and sensitivity.
• This method shows potential for detecting ovarian cancer in CA-125-negative sera.